Amgen Inc. (AMGN)
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) Laps the Stock Market: Here's Why
In the closing of the recent trading day, Amgen (AMGN) stood at $297.32, denoting a +1.18% move from the preceding trading day.
Why Amgen (AMGN) Could Beat Earnings Estimates Again
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
Amgen (AMGN) reached $294.12 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.
Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts
The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Shares Cross Above 200 DMA
In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Amgen Inc. (NASDAQ:AMGN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Adam Elinoff Paul Burton - Senior VP & Chief Medical Officer Casey Capparelli Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst So we have Paul Burton. He's the Chief Medical Officer of the company; and dabbing for the first time, Adam Elinoff, the new IR at Amgen.
